Immatics' IMA402 achieves 32% confirmed response rate in PRAME-high melanoma trial patients

By Public Technologies
  • Immatics announced updated early-stage trial results showing durable tumor responses across advanced solid cancers with IMA402 bispecific therapy and IMA203CD8 cell therapy.
  • IMA402 showed favorable tolerability, supporting development across multiple cancers; results will be presented at the 2026 ESMO meeting.
  • IMA203CD8 results were presented at ESMO, showing durable activity with manageable safety, including in heavily pretreated gynecologic cancers.
  • Development plans include IMA402 combination studies with initial lung cancer data expected in 2027.
  • A pediatric cancer trial of IMA203CD8 is planned to begin in the first half of 2027, supporting broader development across PRAME-positive cancers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immatics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610240230PRIMZONEFULLFEED1001279570) on October 24, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.